ClinicalTrials.gg
CompletedNCT02484729Updated Apr 28, 2017Results posted

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 After Single Ascending Doses to Healthy Males

A Phase 1 interventional study of AZD9977, oral suspension and Placebo, oral suspension in Safety, Tolerability and Pharmacokinetics, sponsored by AstraZeneca. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-28.

Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
196
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

This study will be a randomized, single-blind, placebo-controlled first-in-human study in healthy male subjects to assess the safety, tolerability and pharmacokinetics of single ascending doses of AZD9977. In Part B of this study the regional absorption of AZD9977 along the gastro-intestinal tract will be investigated using the IntelliCap® system in a non-randomized, open-label, fixed-sequence design. The study will be performed at a single study centre.

Read the detailed description

This study will be a randomized, single-blind, placebo-controlled first-in-human study in healthy male subjects to assess the safety, tolerability and pharmacokinetics of single ascending doses of AZD9977. In Part B of this study the regional absorption of AZD9977 along the gastro-intestinal tract will be investigated using the IntelliCap® system in a non-randomized, open-label, fixed-sequence design with oral solution as reference. The study will be performed at a single study centre.

02

Conditions studied

  • Safety
  • Tolerability
  • Pharmacokinetics
  • Healthy Subjects

Keywords

  • AZD9977
  • Safety
  • Tolerability
  • Pharmacokinetics
  • First-in-human
  • Single Ascending Dose
  • Regional absorption
  • Healthy male subjects
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated written prior to any study specific procedures.
  2. Healthy male subjects aged 18 to 50 years with suitable veins for cannulation or repeated venipuncture.
  3. Male subjects have to comply with the restrictions for sexual activity provided to them.
  4. Have a (BMI) between 18 and 30 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive.
  5. Optional: Provision of signed and dated written informed consent for genetic research.

    If a subject declines to participate in the genetic component of the study, there will be no penalty or loss of benefit to the subject. The subject will not be excluded from other aspects of the study described in this protocol.

  6. Able to understand, read and speak the English language.

Exclusion criteria

Exclusion Criteria:

  1. History of any disease or disorder which, in the opinion of the investigator, may either put the potential subject at risk because of participation in the study, or influences the results or the potential subject's ability to participate in the study.
  2. History or presence of GI, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  3. Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of dosing in Part A or the first dose of AZD9977 in Part B.
  4. Any clinically significant abnormalities in hematology, clinical chemistry or urinalysis results, as judged by the investigator.
  5. Any positive result at screening for serum surface antigen (HBsAg), antibody, and (HIV) antibodies.
  6. Abnormal findings in vital signs, after 10 minutes resting in the supine position, defined as any of the following:

    • Systolic blood pressure (SBP) \< 90 mmHg or ≥ 140 mmHg
    • Diastolic blood pressure (DBP) \< 50 mmHg or ≥ 90 mmHg
    • Pulse \< 45 or > 90 bpm
  7. Any clinically important abnormalities in rhythm, conduction or morphology of the (ECG) at screening or pre-dose, as considered by the investigator.
  8. Prolonged > 450 ms or family history of long QT syndrome.
  9. PR (PQ) interval shortening \< 120 ms. PR > 110 ms but \< 120 ms is acceptable if there is no evidence of ventricular pre-excitation.
  10. PR (PQ) interval prolongation > 240ms; intermittent second or third degree atrioventricular (AV) block, or AV dissociation.

    Wenckebach block while asleep is not exclusive.

  11. Persistent or intermittent complete bundle branch block (BBB), incomplete bundle branch block (IBBB), or intraventricular conduction delay (IVCD) with QRS > 110 ms.

    QRS > 110 ms but \< 115 ms are acceptable if there is no evidence of ventricular hypertrophy or pre-excitation.

  12. Serum potassium higher than 5.0 mmol/L at screening or admission to the study center (Day -1).
  13. Known or suspected history of drug abuse as judged by the investigator.
  14. Current smokers or those who have smoked or used nicotine products within the previous 3 months.
  15. History of alcohol abuse or excessive intake of alcohol as judged by the investigator.
  16. Positive screen for drugs of abuse, alcohol or cotinine at screening or admission to the study center.
  17. History of severe allergy/ or ongoing clinically important allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to AZD9977.
  18. Excessive intake of caffeine containing drinks or food (e.g., coffee, tea and chocolate) as judged by the investigator.
  19. Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks prior to dosing in Part A or the first dose of AZD9977 in Part B.
  20. Use of any prescribed or non-prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during 2 weeks prior to dosing in Part A or the first dose of AZD9977 in Part B, or longer if the medication has a long half-life.
  21. Plasma donation within one month of screening or any blood donation/blood loss > 500 mL during the 3 months prior to screening.
  22. Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months of dosing in Part A or the first dose of AZD9977 in Part B in this study. The period of exclusion begins 3 months after the final dose or one month after the last visit whichever is the longest.

    Note: Subjects consented and screened, but not randomized in this study or a previous phase I study, are not excluded.

  23. Involvement of any AstraZeneca or study site employee or their close relatives.
  24. Judgment by the investigator that the subject should not participate in the study if they have any ongoing or recent (i.e., during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions and requirements.
  25. Subjects who are vegans or have medical dietary restrictions (vegetarians may be included in the study).
  26. Subjects who cannot communicate reliably with the investigator.
  27. Vulnerable subjects, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.

    In addition, any of the following is regarded as a criterion for exclusion from the genetic research:

  28. Previous bone marrow transplant.
  29. Non-leukocyte depleted whole blood transfusion within 120 days of the date of the genetic sample collection.

    Criteria applicable to Part B only:

  30. Subjects with pacemakers or other implanted electro-medical devices.
  31. Subjects with swallowing disorders.
  32. Subjects with pre-planned MRI examination.
  33. Subjects not willing to have an abdominal X-ray performed if the IntelliCap® capsule has not been retrieved within one week after ingestion.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
196 participants (actual)

Study arms

  • Experimental
    AZD9977 oral suspension, single doses

    In Part A up to 10 cohorts with single ascending doses with AZD9977 as oral suspension. In Part B AZD9977 as oral suspension in IntelliCap® capsule

    Drug: AZD9977, oral suspension

  • Placebo comparator
    Placebo, oral suspension, single doses

    In Part A up to 10 cohorts with single doses with matching placebo to AZD9977

    Drug: Placebo, oral suspension

  • Experimental
    AZD9977, oral solution, single dose

    In Part B, of oral solution of AZD9977 will be used as reference

    Drug: AZD9977, oral solution

Interventions

  • Single ascending doses of AZD9977 oral suspension (Part A) Single dose of AZD9977 oral suspension in IntelliCap® capsule in regional absorption part (Part B)

  • DrugPlacebo, oral suspension

    Matching placebo

  • AZD9977, single dose of oral solution in Part B as reference

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability of AZD9977 by Assessing the Percentage of Participants With Adverse Events

    To assess the safety and tolerability of single ascending doses of AZD9977

    Time frame: For up to 45 days, i.e. from Screening to Follow-up

  2. Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Pulse Rate

    To assess the safety and tolerability of single ascending doses of AZD9977

    Time frame: For up to 45 days, i.e. from Screening to Follow-up

  3. Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Trends in 12-lead Electrocardiograms

    To assess the safety and tolerability of single ascending doses of AZD9977

    Time frame: For up to 45 days, i.e. from Screening to Follow-up

  4. Safety and Tolerability of AZD9977 by Number of Participants With Clinically Significant Trends in Cardiac Telemetry

    To assess the safety and tolerability of single ascending doses of AZD9977

    Time frame: For up to 4 days, i.e. on the day before each dosing and for 24 hours after each dosing

  5. Safety and Tolerability of AZD9977 by Assessing the Number of Subjects With Adverse Events

    To assess the safety and tolerability of single ascending doses of AZD9977

    Time frame: For up to 45 days, i.e. from Screening to Follow-up

  6. Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Blood Pressure

    To assess the safety and tolerability of single ascending doses of AZD9977

    Time frame: For up to 45 days, i.e. from Screening to Follow-up

  7. Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Hematology

    To assess the safety and tolerability of single ascending doses of AZD9977

    Time frame: For up to 45 days, i.e. from Screening to Follow-up

  8. Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Clinical Chemistry

    To assess the safety and tolerability of single ascending doses of AZD9977

    Time frame: For up to 45 days, i.e. from Screening to Follow-up

  9. Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Urinalysis

    To assess the safety and tolerability of single ascending doses of AZD9977

    Time frame: For up to 45 days, i.e. from Screening to Follow-up

Secondary outcomes

  1. Area Under the Plasma Concentration Versus Time Curve (AUC) From Zero Extrapolated to Infinity.

    To assess plasma pharmacokinetic parameters following single ascending doses of AZD977

    Time frame: Pre-dose and post-dose upto 48 hrs

  2. Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Analyte concentrationAUC(0-t)

    To assess plasma pharmacokinetic parameters following single ascending doses of AZD977

    Time frame: Pre-dose and post-dose upto 48 hrs

  3. Observed Maximum Concentration (Cmax)

    To assess plasma pharmacokinetic parameters following single ascending doses of AZD977

    Time frame: Pre-dose and post-dose upto 48 hrs

  4. Time to Maximum Observed Plasma Concentration (t Max)

    To assess plasma pharmacokinetic parameters following single ascending doses of AZD977

    Time frame: Pre-dose and post-dose upto 48 hrs

  5. Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t1/2λz)

    To assess plasma pharmacokinetic parameters following single ascending doses of AZD977

    Time frame: Pre-dose and post-dose upto 48 hrs

  6. Apparent Clearance (CL/F)

    To assess plasma pharmacokinetic parameters following single ascending doses of AZD977

    Time frame: Pre-dose and post-dose upto 48 hrs

  7. Apparent Volume of Distribution (Vz/F)

    To assess plasma pharmacokinetic parameters following single ascending doses of AZD977

    Time frame: Pre-dose and post-dose upto 48 hrs

  8. Cumulative Amount of Unchanged Drug Excreted Into Urine [Ae (0-48)]

    To assess urine pharmacokinetic parameters following single ascending doses of AZD9977

    Time frame: Pre-dose and post-dose upto 48 hrs

  9. Fraction Excreted Unchanged in Urine[Fe (0-48)]

    To assess percentage of the total drug excreted in the urine that was unchanged following single ascending doses of AZD9977

    Time frame: Pre-dose and post-dose upto 48 hrs

  10. Renal Clearance of Drug From Plasma [CLR (0-48)]

    To assess urine pharmacokinetic parameters following single ascending doses of AZD9977

    Time frame: Pre-dose and post-dose upto 48 hrs

07

Results

Posted Mar 24, 2017

Participant flow

This study was conducted at PAREXEL International, Early Phase Clinical Unit London, United Kingdom.

Participant flow — Overall Study
MilestonePart A- PlaceboPart A - 5 mg AZD9977Part A - 25 mg AZD9977Part A - 100 mg AZD9977Part A - 200 mg AZD9977Part A - 400 mg AZD9977Part A - 800 mg AZD9977Part A - 800 mg AZD9977 (Split Doses)Part A - 1200 mg AZD9977 (Split Doses)Part B
Started16666565668
Completed16666565667
Not completed0000000001
Withdrew: Failure of intellicap error0000000001

Outcome measures

PrimarySafety and Tolerability of AZD9977 by Assessing the Percentage of Participants With Adverse Events

To assess the safety and tolerability of single ascending doses of AZD9977

Time frame:
For up to 45 days, i.e. from Screening to Follow-up
Reported as:
Number · percentage of participants
Safety and Tolerability of AZD9977 by Assessing the Percentage of Participants With Adverse Events
percentage of participantsPart A- PlaceboPart A - 5 mg AZD9977Part A - 25 mg AZD9977Part A - 100 mg AZD9977Part A - 200 mg AZD9977Part A - 400 mg AZD9977Part A - 800 mg AZD9977Part A - 800 mg AZD9977 (Split Doses)Part A - 1200 mg AZD9977 (Split Doses)Part B
Safety and Tolerability of AZD9977 by Assessing the Percentage of Participants With Adverse Events43.816.733.333.320.033.3033.316.737.5
PrimarySafety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Pulse Rate

To assess the safety and tolerability of single ascending doses of AZD9977

Time frame:
For up to 45 days, i.e. from Screening to Follow-up
Reported as:
Number · Number of Participants
Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Pulse Rate
Number of ParticipantsPart A- PlaceboPart A - 5 mg AZD9977Part A - 25 mg AZD9977Part A - 100 mg AZD9977Part A - 200 mg AZD9977Part A - 400 mg AZD9977Part A - 800 mg AZD9977Part A - 800 mg AZD9977 (Split Doses)Part A - 1200 mg AZD9977 (Split Doses)Part B
Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Pulse Rate0000000000
PrimarySafety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Trends in 12-lead Electrocardiograms

To assess the safety and tolerability of single ascending doses of AZD9977

Time frame:
For up to 45 days, i.e. from Screening to Follow-up
Reported as:
Number · Number of participants
Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Trends in 12-lead Electrocardiograms
Number of participantsPart A- PlaceboPart A - 5 mg AZD9977Part A - 25 mg AZD9977Part A - 100 mg AZD9977Part A - 200 mg AZD9977Part A - 400 mg AZD9977Part A - 800 mg AZD9977Part A - 800 mg AZD9977 (Split Doses)Part A - 1200 mg AZD9977 (Split Doses)Part B
Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Trends in 12-lead Electrocardiograms0000000000
PrimarySafety and Tolerability of AZD9977 by Number of Participants With Clinically Significant Trends in Cardiac Telemetry

To assess the safety and tolerability of single ascending doses of AZD9977

Time frame:
For up to 4 days, i.e. on the day before each dosing and for 24 hours after each dosing
Reported as:
Number · Number of Participants
Safety and Tolerability of AZD9977 by Number of Participants With Clinically Significant Trends in Cardiac Telemetry
Number of ParticipantsPart A- PlaceboPart A - 5 mg AZD9977Part A - 25 mg AZD9977Part A - 100 mg AZD9977Part A - 200 mg AZD9977Part A - 400 mg AZD9977Part A - 800 mg AZD9977Part A - 800 mg AZD9977 (Split Doses)Part A - 1200 mg AZD9977 (Split Doses)Part B
Safety and Tolerability of AZD9977 by Number of Participants With Clinically Significant Trends in Cardiac Telemetry0000000000
PrimarySafety and Tolerability of AZD9977 by Assessing the Number of Subjects With Adverse Events

To assess the safety and tolerability of single ascending doses of AZD9977

Time frame:
For up to 45 days, i.e. from Screening to Follow-up
Reported as:
Number · Number of Participants
Safety and Tolerability of AZD9977 by Assessing the Number of Subjects With Adverse Events
Number of ParticipantsPart A- PlaceboPart A - 5 mg AZD9977Part A - 25 mg AZD9977Part A - 100 mg AZD9977Part A - 200 mg AZD9977Part A - 400 mg AZD9977Part A - 800 mg AZD9977Part A - 800 mg AZD9977 (Split Doses)Part A - 1200 mg AZD9977 (Split Doses)Part B
Safety and Tolerability of AZD9977 by Assessing the Number of Subjects With Adverse Events7122120213
PrimarySafety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Blood Pressure

To assess the safety and tolerability of single ascending doses of AZD9977

Time frame:
For up to 45 days, i.e. from Screening to Follow-up
Reported as:
Number · Number of Participants
Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Blood Pressure
Number of ParticipantsPart A- PlaceboPart A - 5 mg AZD9977Part A - 25 mg AZD9977Part A - 100 mg AZD9977Part A - 200 mg AZD9977Part A - 400 mg AZD9977Part A - 800 mg AZD9977Part A - 800 mg AZD9977 (Split Doses)Part A - 1200 mg AZD9977 (Split Doses)Part B
Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Blood Pressure0000000000
PrimarySafety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Hematology

To assess the safety and tolerability of single ascending doses of AZD9977

Time frame:
For up to 45 days, i.e. from Screening to Follow-up
Reported as:
Number · Number of participants
Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Hematology
Number of participantsPart A- PlaceboPart A - 5 mg AZD9977Part A - 25 mg AZD9977Part A - 100 mg AZD9977Part A - 200 mg AZD9977Part A - 400 mg AZD9977Part A - 800 mg AZD9977Part A - 800 mg AZD9977 (Split Doses)Part A - 1200 mg AZD9977 (Split Doses)Part B
Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Hematology0000000000
PrimarySafety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Clinical Chemistry

To assess the safety and tolerability of single ascending doses of AZD9977

Time frame:
For up to 45 days, i.e. from Screening to Follow-up
Reported as:
Number · Number of participants
Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Clinical Chemistry
Number of participantsPart A- PlaceboPart A - 5 mg AZD9977Part A - 25 mg AZD9977Part A - 100 mg AZD9977Part A - 200 mg AZD9977Part A - 400 mg AZD9977Part A - 800 mg AZD9977Part A - 800 mg AZD9977 (Split Doses)Part A - 1200 mg AZD9977 (Split Doses)Part B
Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Clinical Chemistry0000000000
PrimarySafety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Urinalysis

To assess the safety and tolerability of single ascending doses of AZD9977

Time frame:
For up to 45 days, i.e. from Screening to Follow-up
Reported as:
Number · Number of participants
Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Urinalysis
Number of participantsPart A- PlaceboPart A - 5 mg AZD9977Part A - 25 mg AZD9977Part A - 100 mg AZD9977Part A - 200 mg AZD9977Part A - 400 mg AZD9977Part A - 800 mg AZD9977Part A - 800 mg AZD9977 (Split Doses)Part A - 1200 mg AZD9977 (Split Doses)Part B
Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Urinalysis0000000000
SecondaryArea Under the Plasma Concentration Versus Time Curve (AUC) From Zero Extrapolated to Infinity.

To assess plasma pharmacokinetic parameters following single ascending doses of AZD977

Time frame:
Pre-dose and post-dose upto 48 hrs
Reported as:
Geometric mean · h.nmol/L
Area Under the Plasma Concentration Versus Time Curve (AUC) From Zero Extrapolated to Infinity.
h.nmol/LPart A - 5 mg AZD9977Part A - 25 mg AZD9977Part A - 100 mg AZD9977Part A - 200 mg AZD9977Part A - 400 mg AZD9977Part A - 800 mg AZD9977Part A - 800 mg AZD9977 (Split Doses)Part A - 1200 mg AZD9977 (Split Doses)Intellicap Device (Part B)Oral Suspension (Part B)
Area Under the Plasma Concentration Versus Time Curve (AUC) From Zero Extrapolated to Infinity.514.4 ± 13.42473 ± 24.59576 ± 51.923810 ± 33.736210 ± 28.538060 ± 37.298910 ± 29.7105700 ± 30.52256 ± 32.63294 ± 32.9
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Analyte concentrationAUC(0-t)

To assess plasma pharmacokinetic parameters following single ascending doses of AZD977

Time frame:
Pre-dose and post-dose upto 48 hrs
Reported as:
Geometric mean · h.nmol/L
Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Analyte concentrationAUC(0-t)
h.nmol/LPart A - 5 mg AZD9977Part A - 25 mg AZD9977Part A - 100 mg AZD9977Part A - 200 mg AZD9977Part A - 400 mg AZD9977Part A - 800 mg AZD9977Part A - 800 mg AZD9977 (Split Doses)Part A - 1200 mg AZD9977 (Split Doses)Intellicap Device (Part B)Oral Suspension (Part B)
Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Analyte concentrationAUC(0-t)482.7 ± 14.92429 ± 24.79419 ± 52.223470 ± 34.235650 ± 26.034190 ± 16.182720 ± 35.693750 ± 37.51754 ± 38.13136 ± 31.5
SecondaryObserved Maximum Concentration (Cmax)

To assess plasma pharmacokinetic parameters following single ascending doses of AZD977

Time frame:
Pre-dose and post-dose upto 48 hrs
Reported as:
Geometric mean · nmol/L
Observed Maximum Concentration (Cmax)
nmol/LPart A - 5 mg AZD9977Part A - 25 mg AZD9977Part A - 100 mg AZD9977Part A - 200 mg AZD9977Part A - 400 mg AZD9977Part A - 800 mg AZD9977Part A - 800 mg AZD9977 (Split Doses)Part A - 1200 mg AZD9977 (Split Doses)Intellicap Device (Part B)Oral Suspension (Part B)
Observed Maximum Concentration (Cmax)201.6 ± 27.7952.0 ± 20.93367 ± 41.35966 ± 40.67243 ± 27.77149 ± 17.214310 ± 29.116700 ± 29.2161.2 ± 36.8790.9 ± 22.9
SecondaryTime to Maximum Observed Plasma Concentration (t Max)

To assess plasma pharmacokinetic parameters following single ascending doses of AZD977

Time frame:
Pre-dose and post-dose upto 48 hrs
Reported as:
Median · Hour (h)
Time to Maximum Observed Plasma Concentration (t Max)
Hour (h)Part A - 5 mg AZD9977Part A - 25 mg AZD9977Part A - 100 mg AZD9977Part A - 200 mg AZD9977Part A - 400 mg AZD9977Part A - 800 mg AZD9977Part A - 800 mg AZD9977 (Split Doses)Part A - 1200 mg AZD9977 (Split Doses)Intellicap Device (Part B)Oral Suspension (Part B)
Time to Maximum Observed Plasma Concentration (t Max)0.50 (0.50 to 1.08)0.99 (0.50 to 1.02)0.50 (0.50 to 1.02)1.00 (0.48 to 1.00)0.88 (0.38 to 1.50)0.75 (0.50 to 1.00)3.51 (3.50 to 4.50)3.74 (2.50 to 4.50)4.02 (1.98 to 5.52)0.75 (0.23 to 1.50)
SecondaryHalf-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t1/2λz)

To assess plasma pharmacokinetic parameters following single ascending doses of AZD977

Time frame:
Pre-dose and post-dose upto 48 hrs
Reported as:
Mean · Hour (h)
Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t1/2λz)
Hour (h)Part A - 5 mg AZD9977Part A - 25 mg AZD9977Part A - 100 mg AZD9977Part A - 200 mg AZD9977Part A - 400 mg AZD9977Part A - 800 mg AZD9977Part A - 800 mg AZD9977 (Split Doses)Part A - 1200 mg AZD9977 (Split Doses)Intellicap Device (Part B)Oral Suspension (Part B)
Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t1/2λz)1.741 ± 0.17531.755 ± 0.29237.161 ± 4.39710.00 ± 1.9339.618 ± 3.41222.99 ± 6.52721.17 ± 12.1821.68 ± 3.49511.60 ± 6.0816.145 ± 3.365
SecondaryApparent Clearance (CL/F)

To assess plasma pharmacokinetic parameters following single ascending doses of AZD977

Time frame:
Pre-dose and post-dose upto 48 hrs
Reported as:
Mean · L/h
Apparent Clearance (CL/F)
L/hPart A - 5 mg AZD9977Part A - 25 mg AZD9977Part A - 100 mg AZD9977Part A - 200 mg AZD9977Part A - 400 mg AZD9977Part A - 800 mg AZD9977Part A - 800 mg AZD9977 (Split Doses)Part A - 1200 mg AZD9977 (Split Doses)Intellicap Device (Part B)Oral Suspension (Part B)
Apparent Clearance (CL/F)24.52 ± 3.39125.89 ± 5.54628.46 ± 11.0821.84 ± 5.81228.49 ± 7.39254.34 ± 19.1620.99 ± 6.68329.38 ± 8.43045.97 ± 13.0331.82 ± 10.79
SecondaryApparent Volume of Distribution (Vz/F)

To assess plasma pharmacokinetic parameters following single ascending doses of AZD977

Time frame:
Pre-dose and post-dose upto 48 hrs
Reported as:
Mean · L
Apparent Volume of Distribution (Vz/F)
LPart A - 5 mg AZD9977Part A - 25 mg AZD9977Part A - 100 mg AZD9977Part A - 200 mg AZD9977Part A - 400 mg AZD9977Part A - 800 mg AZD9977Part A - 800 mg AZD9977 (Split Doses)Part A - 1200 mg AZD9977 (Split Doses)Intellicap Device (Part B)Oral Suspension (Part B)
Apparent Volume of Distribution (Vz/F)61.50 ± 9.72464.52 ± 13.40266.1 ± 180.6315.8 ± 111.9401.9 ± 180.01712 ± 123.7652.5 ± 414.0897.0 ± 210.6720.1 ± 348.2269.4 ± 142.2
SecondaryCumulative Amount of Unchanged Drug Excreted Into Urine [Ae (0-48)]

To assess urine pharmacokinetic parameters following single ascending doses of AZD9977

Time frame:
Pre-dose and post-dose upto 48 hrs
Reported as:
Mean · nmol
Cumulative Amount of Unchanged Drug Excreted Into Urine [Ae (0-48)]
nmolPart A - 5 mg AZD9977Part A - 25 mg AZD9977Part A - 100 mg AZD9977Part A - 200 mg AZD9977Part A - 400 mg AZD9977Part A - 800 mg AZD9977Part A - 800 mg AZD9977 (Split Doses)Part A - 1200 mg AZD9977 (Split Doses)
Cumulative Amount of Unchanged Drug Excreted Into Urine [Ae (0-48)]2491 ± 213.412440 ± 281859700 ± 21910122800 ± 27020189700 ± 46420178600 ± 32530428600 ± 93430503400 ± 132300
SecondaryFraction Excreted Unchanged in Urine[Fe (0-48)]

To assess percentage of the total drug excreted in the urine that was unchanged following single ascending doses of AZD9977

Time frame:
Pre-dose and post-dose upto 48 hrs
Reported as:
Mean · Percentage
Fraction Excreted Unchanged in Urine[Fe (0-48)]
PercentagePart A - 5 mg AZD9977Part A - 25 mg AZD9977Part A - 100 mg AZD9977Part A - 200 mg AZD9977Part A - 400 mg AZD9977Part A - 800 mg AZD9977Part A - 800 mg AZD9977 (Split Doses)Part A - 1200 mg AZD9977 (Split Doses)
Fraction Excreted Unchanged in Urine[Fe (0-48)]19.90 ± 1.70519.88 ± 4.50223.84 ± 8.75024.53 ± 5.39618.94 ± 4.6358.917 ± 1.62421.40 ± 4.66416.75 ± 4.402
SecondaryRenal Clearance of Drug From Plasma [CLR (0-48)]

To assess urine pharmacokinetic parameters following single ascending doses of AZD9977

Time frame:
Pre-dose and post-dose upto 48 hrs
Reported as:
Mean · L/h
Renal Clearance of Drug From Plasma [CLR (0-48)]
L/hPart A - 5 mg AZD9977Part A - 25 mg AZD9977Part A - 100 mg AZD9977Part A - 200 mg AZD9977Part A - 400 mg AZD9977Part A - 800 mg AZD9977Part A - 800 mg AZD9977 (Split Doses)Part A - 1200 mg AZD9977 (Split Doses)
Renal Clearance of Drug From Plasma [CLR (0-48)]5.018 ± 0.58185.061 ± 1.1956.114 ± 1.5335.230 ± 1.0285.371 ± 0.68805.700 ± 1.0975.274 ± 0.98175.319 ± 0.5086

Adverse events

Collected over SAEs will be collected from the signing of informed consent and AEs from randomization until the final follow-up visit in Part A, and from first dosing until the final follow-up visit in Part B.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A- Placebo—0/16 (0%)7/16 (43.8%)
Part A - 5 mg AZD9977—0/6 (0%)1/6 (16.7%)
Part A - 25 mg AZD9977—0/6 (0%)2/6 (33.3%)
Part A - 100 mg AZD9977—0/6 (0%)2/6 (33.3%)
Part A - 200 mg AZD9977—0/5 (0%)1/5 (20%)
Part A - 400 mg AZD9977—0/6 (0%)1/6 (16.7%)
Part A - 800 mg AZD9977—0/5 (0%)0/5 (0%)
Part A - 800 mg AZD9977 (Split Doses)—0/6 (0%)2/6 (33.3%)
Part A - 1200 mg AZD9977 (Split Doses)—0/6 (0%)1/6 (16.7%)
Part B—0/8 (0%)3/8 (37.5%)
Most frequent other events
Showing 10 of 20
Most frequent other events
EventPart A- PlaceboPart A - 5 mg AZD9977Part A - 25 mg AZD9977Part A - 100 mg AZD9977Part A - 200 mg AZD9977Part A - 400 mg AZD9977Part A - 800 mg AZD9977Part A - 800 mg AZD9977 (Split Doses)Part A - 1200 mg AZD9977 (Split Doses)Part B
NasopharyngitisInfections and infestations0/160/60/60/60/50/60/50/61/62/8
DizzinessNervous system disorders1/161/61/60/61/50/60/50/60/60/8
HeadacheNervous system disorders1/160/60/61/60/50/60/50/60/61/8
BackpainMusculoskeletal and connective tissue disorders0/160/60/61/60/51/60/50/60/60/8
Musculoskeletal painMusculoskeletal and connective tissue disorders0/160/60/60/60/51/60/50/60/60/8
Abdominal distensionGastrointestinal disorders0/160/61/60/60/50/60/50/60/60/8
NauseaGastrointestinal disorders0/160/60/61/60/50/60/50/60/61/8
HyperhidrosisSkin and subcutaneous tissue disorders0/160/60/60/60/50/60/51/60/60/8
PruritusSkin and subcutaneous tissue disorders0/160/60/60/60/50/60/51/60/60/8
Feeling hotGeneral disorders0/160/60/60/60/50/60/51/60/60/8

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Part A- PlaceboPart A - 5 mg AZD9977Part A - 25 mg AZD9977Part A - 100 mg AZD9977Part A - 200 mg AZD9977Part A - 400 mg AZD9977Part A - 800 mg AZD9977Part A - 800 mg AZD9977 (Split Doses)Part A - 1200 mg AZD9977 (Split Doses)Part BTotal
Mean30 ± 632 ± 1130 ± 936 ± 1032 ± 1033 ± 930 ± 632 ± 838 ± 1135 ± 933 ± 9
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Part A- PlaceboPart A - 5 mg AZD9977Part A - 25 mg AZD9977Part A - 100 mg AZD9977Part A - 200 mg AZD9977Part A - 400 mg AZD9977Part A - 800 mg AZD9977Part A - 800 mg AZD9977 (Split Doses)Part A - 1200 mg AZD9977 (Split Doses)Part BTotal
Male1666656566870
08

Study locations

1 site
  • Research Site
    Harrow, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2015, a primary completion of Nov 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2015
First posted
Jun 30, 2015
Start
Jul 2015
Primary completionActual
Nov 2015
CompletionActual
Nov 2015
Results first posted
Mar 24, 2017
Last update
Apr 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02484729
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 30, 2015
Start date
Jul 2015
Primary completion
Nov 2015
Completion
Nov 2015
Results posted
Mar 24, 2017
Last update
Apr 28, 2017

Study contacts

Muna Albayaty, Dr.
principal investigator · PAREXEL Early Phase Clinical Unit London, Level 7, Northwick Park Hospital, Watford Road, Harrow, Middlesex HA1 3UJ, United Kingdom

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD9977

Start the discussion